Regulatory News:
Eurofins Scientific (EUFI.PA), a global scientific leader in bioanalytical testing, with a rapidly developing presence in highly specialised and molecular clinical diagnostics testing and in-vitro diagnostics products, announces the successful closing of the acquisition of SYNLAB's clinical diagnostics operations in Spain and the transfer of operations to Eurofins, which took place on 31 March 2025.
SYNLAB's clinical diagnostics operations in Spain comprise clinical diagnostics testing services, including genetics and anatomical pathology services, provided throughout the country, achieving revenues of approximately €140m in 2024. SYNLAB's operations strongly complement the Eurofins network's existing clinical diagnostics operations in Spain, led by Eurofins Megalab, a specialist in all types of clinical diagnostics testing and in managing intra-hospital laboratories in Spain.
With this acquisition, Eurofins will become a leading clinical diagnostics operator in Spain, with a unique capability to cater to public and private clients and cover all regions in the country. The extensive network of Eurofins clinical diagnostics laboratories and blood collection points will have the capacity to serve more than 10 million patients and process over 100 million laboratory tests annually. Employing a highly specialised workforce of over 2,000 staff and a best-in-class portfolio of clinical diagnostics laboratory tests, Eurofins is capable of providing high-quality services based on the latest technology and scientific medical advances.
Comment from Dr Gilles Martin, Eurofins CEO: "We are pleased to welcome SYNLAB's Spanish clinical diagnostics team to Eurofins. With our newly expanded network, we will be able to provide an even greater service offering to our clients, to whom we are a trusted, technologically advanced partner".
Notes to Editors:
About Eurofins the global leader in bio-analysis
Eurofins is Testing for Life. The Eurofins Scientific SE network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.
With ca. 63,000 staff across a decentralised and entrepreneurial network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.
Eurofins companies' broad range of services are important for the health and safety of people and our planet. The ongoing investment to become fully digital and maintain the best network of state-of-the-art laboratories and equipment supports our objective to provide our customers with high-quality services, innovative solutions and accurate results in the best possible turnaround time (TAT). Eurofins companies are well positioned to support clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the evolving requirements of healthcare practitioners around the world.
The Eurofins network has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, its companies draw on the latest developments in the field of biotechnology and analytical chemistry to offer their clients unique analytical solutions.
Shares in Eurofins Scientific SE are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).
Until it has been lawfully made public widely by Eurofins Scientific SE through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific SE's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific SE disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantees can be made as to their completeness or validity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250331526169/en/
Contacts:
For more information, please visit www.eurofins.com or contact:
Investor Relations
Eurofins Scientific SE
Phone: +32 2 766 1620
E-mail: ir@sc.eurofinseu.com
